NCT00141921View on ClinicalTrials.gov

Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

August 11, 2005

Primary Completion Date

December 19, 2011

Study Completion Date

August 16, 2017

Conditions

Pediatric Plaque Psoriasis

Interventions

DRUG

Etanercept

Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00141921 - Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis | Biotech Hunter | Biotech Hunter